Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (Germany)
The Regents of the University of Michigan (USA)
Iowa State University Research Foundation, Inc. (USA)
Inventor
Zischka, Hans
Dispirito, Alan Angelo
Semrau, Jeremy David
Abstract
The present invention relates to a methanobactin reducing Fe3+ ions to Fe2+ ions for use in medicine and a pharmaceutical composition comprising said methanobactin as well as to a process for reducing Fe3+ ions to Fe2+ ions ex vivo.
Methods for performing non-invasive thrombolysis with ultrasound using, in some embodiments, one or more ultrasound transducers to focus or place a high intensity ultrasound beam onto a blood clot (thrombus) or other vascular inclusion or occlusion (e.g., clot in the dialysis graft, deep vein thrombosis, superficial vein thrombosis, arterial embolus, bypass graft thrombosis or embolization, pulmonary embolus) which would be ablated (eroded, mechanically fractionated, liquefied, or dissolved) by ultrasound energy. The process can employ one or more mechanisms, such as of cavitational, sonochemical, mechanical fractionation, or thermal processes depending on the acoustic parameters selected. This general process, including the examples of application set forth herein, is henceforth referred to as “Thrombolysis.”
A61B 17/22 - Surgical instruments, devices or methods, e.g. tourniquets for removing obstructions in blood vessels, not otherwise provided for
A61B 17/225 - Surgical instruments, devices or methods, e.g. tourniquets for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
3.
Automated Framework For Monitoring Opt-Out Settings
A computer-implemented method is presented for detecting non-compliance with an opt-out decision of a user. The method includes: identifying select statements of a privacy policy for an online tracking entity by analyzing webpages associated with the online tracking entity, where the select statements specify data practices in response to an opt-out decision; detecting transfer of cookies from a web browser to a server, where the cookies are transferred after an opt-out decision by the given user and the server is associated with the given online tracking entity; analyzing content of the detected cookies in relation to the select statements of the privacy policy; and notifying the given user of a violation of the privacy policy in response to determining an inconsistency between the content of the detected cookies and the select statements of the privacy policy.
The present disclosure relates to materials and methods for spatial detection of nucleic acid in a tissue sample or a portion thereof. In particular, provided herein are materials and methods for detecting RNA so as to obtain spatial information about the localization, distribution or expression of genes in a tissue sample. In some embodiments, the materials and methods provided herein enable detection of gene expression in a single cell.
Methods of forming a structural color metal-dielectric-metal (MDM) component via a solution-based process are provided. First, a first metal layer is formed over a treated surface of a substrate by a first electroless deposition process. A surface of the treated substrate is contacted with a first plating bath that comprises a metal selected from the group consisting of: copper, aluminum, silver, alloys, and combinations thereof. A dielectric layer, for example, comprising silicon dioxide, is then deposited over the first metal layer by a sol-gel process. Next, the method comprises forming a second metal layer over the dielectric layer by a second electroless deposition process by contacting the dielectric layer with a second plating bath having a neutral pH and comprising a metal selected from the group consisting of: copper, aluminum, silver, alloys, and combinations thereof.
C23C 18/16 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coating; Contact plating by reduction or substitution, i.e. electroless plating
C23C 18/18 - Pretreatment of the material to be coated
C23C 18/40 - Coating with copper using reducing agents
6.
ANATOMICAL AND FUNCTIONAL ASSESSMENT OF CAD USING MACHINE LEARNING
Anatomical and functional assessment of coronary artery disease (CAD) using machine learning and computational modeling techniques deploying methodologies for non-invasive Fractional Flow Reserve (FFR) quantification based on angiographically derived anatomy and hemodynamics data, relying on machine learning algorithms for image segmentation and flow assessment, and relying on accurate physics-based computational fluid dynamics (CFD) simulation for computation of the FFR.
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Regents of the University of Michigan (USA)
Inventor
Lucas, Peter C.
Mcallister, Linda M.
Kang, Heejae
Chen, Beibei
Maurer, Lisa
Hu, Dong
Cheng, Jing
Klei, Linda
Nikolovska-Coleska, Zaneta
Abstract
Small molecule inhibitors that block the interaction between B-cell lymphoma 10 protein (BCL10) and mucosa- associated lymphoid tissue lymphoma translocation protein 1 (MALT1), thereby inhibiting both the protease and scaffolding activities of MALT1, and MALT1- dependent downstream signaling, including IL-6 and IL-10 secretion by B-cell lymphoma cells and IL-2 transcription and secretion by Jurkat T cells.
C07C 317/26 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/38 - Oxygen atoms in positions 2 and 3, e.g. isatin
C07D 215/14 - Radicals substituted by oxygen atoms
C07D 235/14 - Radicals substituted by nitrogen atoms
C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 263/56 - Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
C07D 333/58 - Radicals substituted by nitrogen atoms
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 215/28 - Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
An epitaxial growth process, referred to as metal-semiconductor junction assisted epitaxy, of ultrawide bandgap aluminum gallium nitride (AlGaN) is disclosed. The epitaxy of AlGaN is performed in metal-rich (e.g., Ga-rich) conditions using plasma-assisted molecular beam epitaxy. The excess Ga layer leads to the formation of a metal-semiconductor junction during the epitaxy of magnesium (Mg)-doped AlGaN, which pins the Fermi level away from the valence band at the growth front. The Fermi level position is decoupled from Mg-dopant incorporation; that is, the surface band bending allows the formation of a nearly n-type growth front despite p-type dopant incorporation. With controlled tuning of the Fermi level by an in-situ metal-semiconductor junction during epitaxy, efficient p-type conduction can be achieved for large bandgap AlGaN.
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.
Disclosed are methods, designs and materials for extending the device operational lifetime of the phosphorescent organic light emitting devices (OLEDs) such as thermally activated delayed fluorescence (TADF) OLEDs. Applying a graded cohost or co-doped emission layer (EML) in the organic layers, both charge transport and charge balance can be precisely engineered to generate a uniform exciton/exciplex profile, preventing the early deaths due to the dense hot-excited states in the device. This invention is aimed at the short lifetime problem of the high efficient phosphorescent OLEDs and TADF OLEDs, especially in the white, blue and deep blue applications.
H10K 50/125 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers specially adapted for multicolour light emission, e.g. for emitting white light
The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
13.
THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING BILIARY TRACT CANCER USING DEVIMISTAT
The invention provides a method for treating biliary tract cancer in a patient in need thereof, comprising the step of intravenously administering to the patient a therapeutically effective amount of (i) devimistat, (ii) gemcitabine, and (iii) cisplatin, in order to treat the biliary tract cancer.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A catalyst system for propane dehydrogenation includes a hollow fiber members packed with a Pt1Sn1/SiO2 catalyst. The hollow fiber membrane includes a separation layer coated on an interior surface of a support tube. The separation layer selectively removes H2 generated during the propane dehydrogenation reaction.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01J 35/10 - Solids characterised by their surface properties or porosity
B01J 37/02 - Impregnation, coating or precipitation
C07C 5/48 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with a hydrogen acceptor with oxygen as an acceptor
15.
VEHICLE STATE-BASED LIGHT PROJECTION COMMUNICATION SYSTEM
A light projection system and method for use in communicating intent of an automated system to a user. The light projection system includes a light projector for projecting light onto a surface adjacent to the light projection system; and a controller for controlling the light projected by the light projector. The controller is configured to, in response to a vehicle state or a traffic state, cause the light to be projected by the light projector so that the light impinges the surface and is reflected as a displayed graphic conveying an intent based on the vehicle state or the traffic state.
B60Q 1/50 - Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor the devices being primarily intended to indicate the vehicle, or parts thereof, or to give signals, to other traffic for indicating other intentions or conditions, e.g. request for waiting or overtaking
B60Q 1/00 - Arrangement of optical signalling or lighting devices, the mounting or supporting thereof or circuits therefor
16.
Hybrid Camera System For Oscuring Personally Identifiable Information
Cameras provide an easy-to-deploy and information-rich datastream for a wide range of ubiquitous sensing and health monitoring applications. However, their unrestricted operation often captures personally identifiable information (PII), preventing their use in privacy-sensitive settings, such as the home, workplace, and hospitals. This disclosure proposes pairing RGB and thermal imaging to robustly detect and remove PII (e.g., an individual's face, skin color, gender, body shape, etc.,) from images before they are stored or sent off the device. A dual camera prototype includes an onboard embedded GPU capable of performing real-time privacy sanitization tasks at 8FPS at under 5 W power consumption. Results show that in the most fail safe settings the system completely removes all PII. In more permissive settings that maintain full compatibility with downstream computer vision methods, 99% of faces are successfully sanitized, facilitating privacy-preserved exercise tracking, in-home activity inferencing, and fall detection.
H04N 23/23 - Cameras or camera modules comprising electronic image sensors; Control thereof for generating image signals from infrared radiation only from thermal infrared radiation
17.
SYSTEMS AND METHODS FOR BIOLOGICAL TRANSFORMATION, CONCENTRATION, AND RECOVERY OF SELENIUM FROM WASTEWATER
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Boltz, Joshua
Rittmann, Bruce
Daigger, Glen
Katz, Lynn
Abstract
The present invention relates to methods for biological wastewater treatment for Se control in Se-laden wastewater. The Se contaminants in the wastewater include the Se oxyanions selenate (SeO42-) and selenite (HSeO3−), which are biochemically reduced and transformed to elemental selenium (Se0) by microorganisms through anaerobic biological reduction. The resulting Se0 is entrained in the biomass, which is further processed to enable the efficient recovery of concentrated Se0.
An optoelectronic system comprising a flexible optoelectronic device, wherein the device comprises a flexible plastic substrate, a coating comprising a glass or a polymer, positioned over the flexible plastic substrate, an anode and a cathode positioned over the coating, an organic heterojunction positioned between the anode and the cathode, comprising a donor material and an acceptor material, and an encapsulating layer comprising a glass or a polymer, positioned over the anode and the cathode. The device further comprises a roller configured to roll the flexible optoelectronic device into a stored position and a frame configured to mount the roller and the optoelectronic device.
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
Plasmonic nanostructures function as an antenna-reactor nanostructure to focus and convert light into thermal/chemical energy, and thus have significant potential for sustainable solar water disinfection. However, the insufficient energy harvesting efficiency resulting from inconsistent nano-features linked with arrangement and scaling is a persistent challenge. An integrated optofluidic fabrication method is presented to produce a high density integrative plasmonic dimer array to enhance solar water disinfection. The plasmonic dimer array is constructed by a combined fabrication of self-assembly monolayer method and block-co-polymer lithography approaches. This combination leads to a two-dimensional hexagonal array of dimer structures consisting of 1.3 nm nanogap. The uniformity and high density of the nanogaps in the plasmonic dimer array allows strong light focusing and a rapid and highly efficient harvesting of photothermal energy at visible and near-infrared region.
H10K 30/35 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains comprising inorganic nanostructures, e.g. CdSe nanoparticles
C02F 1/14 - Treatment of water, waste water, or sewage by heating by distillation or evaporation using solar energy
A tandem photovoltaic (PV) may include III-V semiconductors, silicon, a cathode electrode, an anode electrode, and a gold-to-gold metal bridge electrode. The semiconductors include p-typed and n-typed regions. To form a tandem PV structure, bottom and top PV cells can be independently fabricated. The bottom and the top PV cells are electrically connected by the gold-to-gold metal bridge interconnection, which is positioned between the bottom and the top PV cells. The metal bridge may be formed by cold-welding compression technique. This structure is compatible to the development of tandem PVs as well as thermophotovoltaic (TPV) cells.
H01L 31/0725 - Multiple junction or tandem solar cells
H01L 31/0735 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PN heterojunction type comprising only AIIIBV compound semiconductors, e.g. GaAs/AlGaAs or InP/GaInAs solar cells
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
21.
PHOTOREACTOR FOR PHOTOCATALYSIS, RELATED SYSTEMS, AND RELATED METHODS
The disclosure relates to a photoreactor for performing photocatalytic reactions with a particulate photocatalyst loaded in the reactor. The photoreactor includes an internal wall having an outer surface and defining an interior volume, and a transparent external wall having an outer surface and an opposing inner surface. The internal and external walls are spaced apart so that they together define a reaction volume between the walls. The photoreactor further includes an external light transmission apparatus, such as a light source and/or a light guide, positioned around the external wall and being adapted to transmit light through the external and into the reaction volume. When a particulate photocatalyst loaded in the reaction volume is irradiated by external light transmission apparatus while a reactant is flowing through the reaction volume, a photocatalytic reaction can be performed to form a desired reaction product.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
22.
METHODS, SYSTEMS, AND APPARATUSES FOR DOSE OPTIMIZATION
The United States Government as Represented by the Department of Veterans Affairs (USA)
The Regents of the University of Michigan (USA)
Inventor
Strohbehn, Garth William
Boonstra, Philip Simon
Abstract
Methods, systems and apparatuses for dose optimization is disclosed. A predetermined threshold may be assigned to a medication. Dose-responses from each subject of a plurality of subjects may be collected and evaluated so that a determination may be made regarding whether a particular dose is equal to a true minimum dose with satisfactory efficacy value.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
24.
COMPOSITIONS AND METHODS FOR TREATING WNT-DRIVEN CANCER
The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for targeting oncogenic, Wnt-dependent transcriptional programs in cancers, utilizing as an example adrenocortical carcinoma stratification to treat adrenocortical carcinoma and drugs which have utility for patients stratified by these means.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I,
or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, wherein the variables Ring A, X, R1a, R1b, R2, R3, R4, m, n, and p are described herein, which function as dual inhibitors of EGFR proteins and PI3K proteins. The disclosure further relates to the use of the compounds described herein as therapeutics for the treatment of diseases and conditions mediated by EGFR proteins and/or PI3K proteins, such as cancer and other diseases.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Provided herein is a biomaterial comprising a sensor system comprising a donor fluorophore linked to a target binding moiety (TBM) and an acceptor molecule linked to a TBM, wherein, when the TBM linked to the donor fluorophore and the TBM linked to the acceptor molecule binds to a target, a resonance energy transfer (RET; e.g., Forster (or Fluorescence) resonance energy transfer (FRET), bioluminescent resonance energy transfer (BRET), chemiluminescent resonance energy transfer (CRET), or a combination thereof) from the donor fluorophore to the acceptor molecule occurs and a detectable signal is produced. An medical device, e.g., an implant, comprising the presently disclosed biomaterial comprising a sensor system is further provided. Related medical devices and solid supports are furthermore provided herein. Use of the biomaterials and medical devices in methods of determining a level of expression of a gene, an RNA, or a protein, is additionally provided.
Provided herein are compositions and methods for preventing, attenuating or treating T cell mediated intestinal disorders. In particular, provided herein are methods for preventing, attenuating or treating T cell mediated intestinal disorders characterized with reduced intestinal epithelial cell (IEC) specific mitochondrial complex II component intrinsic succinate dehydrogenase A (SDHA) activity and/or expression through use of compositions comprising a therapeutic agent capable of preventing and/or hindering reduction of IEC related SDHA activity and/or expression.
Systems, methods, and computer-readable medium storing instructions of using transfer machine learning for predicting drug interaction outcomes include: obtaining a trained machine learning model, obtaining genetic information of pathogens of interest, generating predicted drug interaction outcome data for drug treatments of interest using the machine learning model, and indicating the predicted drug interaction outcome data. The machine learning model may be trained by obtaining training data, classifying the training data into subsets corresponding to different actual outcomes, and generating the machine learning model using the classified subsets. The training data may include drug interaction outcome data having, for each respective pathogen of the pathogens, an outcome of drug treatments applied to the respective pathogen. The predicted drug interaction outcome data may be generated based on the genetic information of the pathogens of interest or genetic information or clinical information of living subjects having the pathogens of interest.
Provided herein are microscope surveillance systems and methods. In particular, provided herein are modular, multi-functional microscope surveillance systems and methods suitable for use in incubators and other environments.
Provided herein is technology relating to polymerization and producing polymers and particularly, but not exclusively, to methods, systems, and compositions for producing articles using three-dimensional printing and for improving control of polymerization using a polymerization photoinhibitor having fast back reaction kinetics such as hexaarylbiimidazole compounds and bridged hexaarylbiimidazole compounds.
An optical phased array device and method for manufacturing an optical phased array for the optical phased array device. The method includes: forming a base layer of a waveguide array on a base substrate, determining a waveguide pattern defining a plurality of waveguide paths, and fabricating a pattern layer of the waveguide array on top of the base layer of the waveguide array according to the determined waveguide pattern. The plurality of waveguide paths branch from a common path and terminate at a plurality of edge emitters, where the plurality of edge emitters are spaced apart from one another along a first axis that extends in the first dimension along an edge of the optical phased array. The spacing of multiple ones of the plurality of emitters along the first axis is aperiodic.
G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
Provided herein are immobilized chiral phosphoric acids and methods of using immobilized chiral phosphoric acids as catalysts for protecting group reactions.
A computer system includes memory hardware configured to store a multitask neural network, an optimization model, a material database, material feature vector inputs, and computer-executable instructions which include training the multitask neural network with the material feature vector inputs to generate a material structural parameter output, obtaining at least one of a target optical perception parameter and a target optical response, supplying the target optical perception parameter or target optical response and at least two of the multiple material data structures of the material database to the multitask neural network to output the at least one predicted material and the predicted structural parameter distribution, processing, by the optimization model, the predicted structural parameter distribution to generate a tuned structural parameter output, and transmitting the at least one predicted material and the tuned structural parameter output to a computing device to facilitate generation of an optical structure.
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
This disclosure relates generally to inhibitors of MHC-I downmodulation, and methods of treating or preventing an HIV infection by administering the inhibitors to a patient in need of treatment thereof.
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
Provided herein is technology relating to preventing and treating gastrointestinal dysbiosis and particularly, but not exclusively, to compositions, methods, systems, and kits for treating and/or preventing Clostridioides difficile infection in an organism.
Disclosed herein are organic photosensitive devices including at least one exciton-blocking charge carrier filter. The filters comprise a mixture of at least one wide energy gap material and at least one electron or hole conducting material. As described herein, the novel filters simultaneously block excitons and conduct the desired charge carrier (electrons or holes).
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
Image guided interventions are performed in a sterile environment. A device is provided for imaging at least a part of a patient, wherein the device includes a detection apparatus having a tunnel through which or into which the patient is configured to be transported for imaging purposes. A sterile cover rolled up or folded is provided at the outside of the tunnel. A covering mechanism is capable of unrolling or unfolding the sterile cover and draping the sterile cover in the tunnel, such that the inner wall of tunnel is at least partially covered by the sterile cover.
A61B 46/10 - Surgical drapes specially adapted for instruments
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
38.
METHOD OF ACTIVATING METAL-ORGANIC FRAMEWORK WITH DIMETHYL ETHER
A method of activating a metal-organic framework material can include solvent exchanging the metal organic framework material with DME and then applying a vacuum to remove the DME and any residual solvent.
The Board of Trustees of the Leland Stanford Junior University (USA)
The Regents of the University of Michigan (USA)
Vanderbilt University (USA)
Inventor
Jaiswal, Siddhartha
Bick, Alexander
Weinstock, Joshua
Abstract
Compositions and methods are provided for the analysis and treatment of conditions relating to clonal hematopoiesis of indeterminate potential (CHIP). In some embodiments, treatment is provided to reduce the progression of CHIP, particularly to reduce the progression to hematologic malignancy and/or heart disease. In other embodiments, methods are provided for determining clonal expansion, for example as a molecular diagnostic test that enables determination of clonal growth rate from a single sample. The method for determining clonal expansion can be applied to identify factors that influence clonal expansion, including environmental, metabolic, microbiome, and genetic.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
40.
MICROFLUIDIC DEVICES AND METHODS FOR THE DEVELOPMENT OF NEURAL TUBE-LIKE TISSUES OR NEURAL SPHEROIDS
The present disclosure provides devices and in vitro methods of developing three-dimensional neural tube-like tissues. In some aspects, the disclosure provides devices and methods of developing three-dimensional neural tube-like tissues comprising forebrain-like, midbrain-like, hindbrain-like, and spinal cord-like tissues. In particular, provided herein microfluidic devices and methods of using the same for generating neural tube-like tissues, such as neural-tube like tissues comprising forebrain-like, midbrain-like, hind-brain-like, and spinal cord-like tissues. In some embodiments, uses of such neural tube-like tissues for research, compound screening and analysis, disease modeling, and therapeutics are provided.
C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
41.
NANOFIBROUS TISSUE ENGINEERING MATRICES WITH IMPROVED CLINICAL HANDLING PROPERTIES FOR PERIODONTAL AND CRANIOFACIAL REGENERATION AND METHODS OF MAKING THE SAME
The disclosure relates generally to a tissue engineering matrix with improved clinical handling properties, designed for periodontal and craniofacial regeneration applications and methods of manufacturing the same. In one application, these matrices are fabricated as surgical membranes which serve not only as a protective barrier but also to induce regeneration through controlled release of inductive substances, facilitate regeneration through the tissue integration, and define and maintain dimensional stability in horizontal and/or vertical defects. In another application, these matrices are fabricated as macroporous scaffolds, and the novel chemistry serves to deliver a three-dimensional environment capable of facilitating tissue ingrowth, vascularization, extracellular matrix deposition and remodeling, and tissue regeneration.
Described herein are compounds of Formula I and conjugates of Formula I′ and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Oncopia Therapeutics, Inc. d/b/a Proteovant Therapeutics, Inc. (USA)
Inventor
Wang, Shaomeng
Chen, Zhixiang
Wu, Dimin
Acharyya, Ranjan Kumar
Xiang, Weiguo
Rej, Rohan
Bai, Longchuan
Zhang, Xuqing
Xu, Guozhang
Abstract
Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
44.
ELECTROHYDRODYNAMIC PRINTER WITH FLUIDIC EXTRACTOR
An electrohydrodynamic printer has a fluidic extractor. A stream of liquid or carrier fluid at a different electrical potential than the printing fluid passes by an extraction opening to extract printing fluid from the extraction opening. The stream of liquid can be a continuous stream, a uniform stream of droplets, or a non-uniform stream of droplets. The extracted printing fluid can merge with the extraction fluid to be carried to a printing surface for deposition. The stream of extraction fluid can be intermittently charged to intermittently extract printing fluid such that selective portions of the stream do not extract printing fluid.
The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Techniques are provided that identify and localize on to reentrant and ectopic patterns of electrical activation in the heart wall. These patterns may correspond to atrial fibrillation, ventricular fibrillation, or other heart arrhythmia conditions. The techniques detect these patterns of electrical activity using a multi-lead an intra-cavitary catheter that, along with a controller, is able to track, over a multi-dimensional cubic space, reentrant activity and identify filaments in the heart cavity. The intra-cavitary catheter includes multiple conducting poles positioned in a configuration relative to each other and functioning as either or both sensing and active poles for measuring electrical pathways in the heart wall and over the multi-dimensional space.
Provided herein are methods for the treatment and prevention of dry macular degeneration via the pharmacologic activation of autophagy without direct inhibition of mammalian target of rapamycin (mTOR), for example by administration of flubendazole.
Provided herein are devices, systems, and methods for treating kidney stones. In particular, provided herein are irrigation and pump systems for use with endoscopic (e.g., ureteroscope) devices, and related methods for use in treating kidney stones and other applications.
A61B 1/015 - Control of fluid supply or evacuation
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
49.
COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES
Accordingly, the present invention relates compositions comprising synthetic HDL (sHDL) nanoparticles, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings). In particular, the present invention provides compositions comprising sHDL nanoparticles for purposes of preventing, attenuating, and/or treating sepsis and sepsis related disorders in a subject, conditions and symptoms caused by a viral infection (e.g., COVID-19)) in a subject, and conditions and symptoms caused by thrombosis in a subject.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
50.
CROSSLINKED ION-EXCHANGE MATERIALS, RELATED METHODS, AND RELATED ARTICLES
The disclosure relates to crosslinked ion-exchange materials (IEM), related methods of making lEMs, and related articles including IEMs. The IEMs can be formed by providing a reaction solution including a charged vinyl monomer, a polyfunctional vinyl crosslinking monomer, a vinyl polymerization initiator, and water; and then performing vinyl polymerization in the reaction solution to form the IEM as a crosslinked reaction product. The reaction solution contains primarily or only water as a solvent for the vinyl monomers. The resulting crosslinked reaction product has a combination of high ionic-exchange capacity (IEC) values coupled with low water uptake and/or low water mass fraction values, which make it suitable for use in various ion-exchange applications.
The present disclosure relates to materials and methods for spatial detection of nucleic acid in a tissue sample or a portion thereof. In particular, provided herein are materials and methods for detecting RNA so as to obtain spatial information about the localization, distribution or expression of genes in a tissue sample. In some embodiments, the materials and methods provided herein enable detection of gene expression in a single cell.
The disclosure provides biocatalysts that halogenate complex chemical compounds in specific and predictable ways. Also disclosed are halogenated complex organic compounds. The disclosure further provides methods for the halogenation of complex chemical compounds and methods of inhibiting the contraction of smooth muscle in mammals.
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
53.
Designing Chemical or Genetic Perturbations using Artificial Intelligence
The following relates generally to identifying perturbations (e.g., chemical perturbations, or genetic perturbations), drug treatments, and/or protein sequences. Some embodiments include a machine learning algorithm comprising a first network that converts perturbations into real-valued vector representations of the perturbations; a second network that converts cell states into real-valued vector representations of the cell states; and a third network that maps relationships between: (i) the real-valued vector representations of the perturbations, and (ii) the real-valued vector representations of the cell states. Some embodiments use the machine learning algorithm to identify a perturbation that will cause a starting cell state to transition to a target cell state by inputting the starting cell state and the target cell state into the machine learning algorithm.
A computer includes a processor and a memory, and the memory stores instructions executable by the processor to jointly train a geometric NeRF multilayer perceptron (MLP) and a color NeRF MLP to model a scene using an occupancy grid map, camera data of the scene from a camera, and lidar data of the scene from a lidar; supervise the geometric NeRF MLP with the lidar data during the joint training; and supervise the color NeRF MLP with the camera data during the joint training. The geometric NeRF MLP is a neural radiance field modeling a geometry of the scene, and the color NeRF MLP is a neural radiance field modeling colors of the scene.
The present disclosure provides means such as uses, nanoparticles, solutions, methods, kits and systems for screening target proteins for self-association properties (viscosity and opalescence) in ultra-dilute solutions. They provide means for screening a large number of target proteins at orders of magnitude lower concentrations than end-use formulations.
A method for fabricating an organic electronic device comprises providing a plurality of photoresist structures on a substrate, the substrate having a first electrode layer, the photoresist structures having a bottom surface attached to the substrate and a top surface opposite the bottom surface, the top surface having a dimension greater than a dimension of the bottom surface, positioning a mask over the structures, the mask having a plurality of openings, and depositing an emissive material over the substrate through at least one of the plurality of openings to form at least one emissive element. An organic electronic device and a method of fabricating an organic electronic component are also described.
Provided herein are compositions and methods for the treatment of cancer by activating the spindle assembly checkpoint (SAC) in cells. In particular, dimerized Mps1 and Spc105/KNL1 constructs are provided as tunable activators of SAC, allowing for control of chromosome segregation accuracy and prevention of aneuploidies that are common in cancer.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The disclosure is directed to compositions and methods for inhibiting an allergic reaction to two or more food allergens. The compositions comprise a nanoemulsion and at least one of the two or more food allergens.
The disclosure is directed to a monoclonal antibody. or an antigen-binding fragment thereof. directed against fibrils of amyloid beta (Aβ) peptides, as well as a method of treating and diagnosing neurodegenerative diseases using the monoclonal antibody.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
60.
ANALYTE DETECTION USING FLUOROGENIC PROBES OR MULTIPLEX TECHNOLOGIES
Provided herein is technology relating to detecting analytes and particularly, but not exclusively, to methods, compositions, systems, and kits for detecting analytes using fluorogenic probes and multiplex technologies.
G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/557 - Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Apparatus and methods are provided for applying ultrasound pulses into tissue or a medium in which the peak negative pressure (P−) of one or more negative half cycle(s) of the ultrasound pulses exceed(s) an intrinsic threshold of the tissue or medium, to directly form a dense bubble cloud in the tissue or medium without shock-scattering. In one embodiment, a microtripsy method of Histotripsy therapy comprises delivering an ultrasound pulse from an ultrasound therapy transducer into tissue, the ultrasound pulse having at least a portion of a peak negative pressure half-cycle that exceeds an intrinsic threshold in the tissue to produce a bubble cloud of at least one bubble in the tissue, and generating a lesion in the tissue with the bubble cloud. The intrinsic threshold can vary depending on the type of tissue to be treated. In some embodiments, the intrinsic threshold in tissue can range from 15-30 MPa.
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
B32B 37/04 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the partial melting of at least one layer
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
63.
Methods To Directly Join Metals To Polymer/Polymer Composites Using Functionally Active Insert Layer
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
The present disclosure provides polypeptides having xanthan gum hydrolytic activity, compositions, and uses thereof. The present disclosure also provides, polynucleotides, expression vectors, host cells, and genetically modified bacteria encoding xanthanases or xanthan-utilizing gene loci.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Boltz, Joshua
Rittmann, Bruce
Daigger, Glen
Abstract
A biofilm membrane bioreactor system with a bioreactor, at least two membrane plates positioned within the bioreactor, and a plurality of biofilm carriers suspended within the wastewater in the bioreactor. The bioreactor has at least one inlet and at least one outlet. The at least two membrane plates are configured to filter the wastewater to generate permeate and may be formed of a ceramic material. Each of the at least two membrane plates are separated from adjacent membrane plates by a membrane gap that is at least two times larger than a smallest dimension of one of the biofilm carriers.
A phase locked loop (PLL) includes a phase detector configured to receive a reference signal and a feedback signal, wherein the reference signal has a reference frequency, sample the feedback signal, and output a phase detection signal indicative of a phase of the feedback signal. A voltage controlled oscillator is configured to generate an output signal based on the phase detection signal. The output signal has an output frequency greater than the reference frequency. Feedback circuitry is configured to detect a signal edge of the output signal and selectively supply, once per cycle of the reference signal, the detected signal edge of the output signal as the feedback signal
H03L 7/091 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal the phase or frequency detector using a sampling device
H03L 7/093 - Automatic control of frequency or phase; Synchronisation using a reference signal applied to a frequency- or phase-locked loop - Details of the phase-locked loop concerning mainly the frequency- or phase-detection arrangement including the filtering or amplification of its output signal using special filtering or amplification characteristics in the loop
H03K 19/173 - Logic circuits, i.e. having at least two inputs acting on one output; Inverting circuits using specified components using elementary logic circuits as components
67.
SYSTEMS AND METHODS FOR HISTOTRIPSY IMMUNOSENSITIZATION
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventor
Xu, Zhen
Cho, Clifford Suhyun
Abstract
Systems and methods for histotripsy and immunotherapy are provided. In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.
Recent advances in model pruning have enabled sparsity-aware deep neural network accelerators that improve the energy efficiency and performance of inference tasks. SONA, a novel transform-domain neural network accelerator is introduced in which convolution operations are replaced by element-wise multiplications and weights are orthogonally structured to be sparse. SONA employs an output stationary dataflow coupled with an energy-efficient memory organization to reduce the overhead of sparse-orthogonal transform-domain kernels that are concurrently processed while maintaining full multiply-and-accumulate (MAC) array utilization without any conflicts. Weights in SONA are non-uniformly quantized with bit-sparse canonical-signed-digit (BS-CSD) representations to reduce multiplications to simpler additions.
G06F 7/544 - Methods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using unspecified devices for evaluating functions by calculation
69.
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING SARS-COV-2 INFECTION
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical compositions capable of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19). The invention further relates to methods of preventing, treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 vims (e.g., COVID-19), comprising administering to a subject (e.g., a human patient) a pharmaceutical composition comprising lactoferrin, S1RA, entecavir, lomitapide, metoclopramide, bosutinib, thioguanine, fedratinib, Z-FA-FMK, amiodarone, verapamil, gilteritinib, clofazimine, niclosamide, and remdesivir (alone or with additional agents).
Provided herein are processes for synthesizing compounds useful as EGFR modulators. In particular, provided herein are processes for synthesizing Compound A:
Provided herein are processes for synthesizing compounds useful as EGFR modulators. In particular, provided herein are processes for synthesizing Compound A:
Three-dimensional (3D) micro-scale shells are presented with selectively removed regions/openings and which can be used in sensors and actuators, including gyroscopes. Example shells consisting of a suspended ring-shaped resonator that is supported using multiple beams that are not in the plane of the ring and are attached to a support post can be formed. Shells with various sizes and geometries of selectively removed regions and openings allow the creation of micro electromechanical systems (MEMS) sensors and actuators with a wide range of engineered mechanical and electrical properties. These shells can be used to form stacked 3D structures for various types of MEMS sensor and actuator devices, such as resonant gyroscopes, with sense and drive electrodes that conform to the curved profile of the resonant shell using for gyroscopes. 3D shells formed from a starting parent substrate are released and separated from their parent substrate using a number of techniques.
G01C 19/5783 - Mountings or housings not specific to any of the devices covered by groups
G01C 19/00 - Gyroscopes; Turn-sensitive devices using vibrating masses; Turn-sensitive devices without moving masses; Measuring angular rate using gyroscopic effects
B81B 3/00 - Devices comprising flexible or deformable elements, e.g. comprising elastic tongues or membranes
H03H 3/007 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks
G01C 19/5691 - Turn-sensitive devices using vibrating masses, e.g. vibratory angular rate sensors based on Coriolis forces using the phase shift of a vibration node or antinode of essentially three-dimensional vibrators, e.g. wine glass-type vibrators
G01C 19/5684 - Turn-sensitive devices using vibrating masses, e.g. vibratory angular rate sensors based on Coriolis forces using the phase shift of a vibration node or antinode of essentially two-dimensional vibrators, e.g. ring-shaped vibrators the devices involving a micromechanical structure
B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
H03H 9/24 - Constructional features of resonators of material which is not piezoelectric, electrostrictive, or magnetostrictive
In various aspects, the present disclosure provides an example autonomous microsystem for immersion into a fluid. The autonomous microsystem includes electronics, a power source, and a packaging system that surrounds the electronics and the power source. The electronics can be configured to sense and record one or more environmental conditions. The packaging system may include a deformable shell that defines an internal space and a plurality of filler particles disposed in the internal space and configured to control a density of the autonomous microsystem in relation to the fluid. The filler particles may comprise a low-density material having a bulk density greater than or equal to about 100 kg/m3 and less than or equal to about 1,000 kg/m3 and have a packing density greater than or equal to about 1011/m3 and less than or equal to about 1021/m3.
A device for radiation detection includes a first electrode, a second electrode spaced apart from the first electrode, and a macroscale structure disposed between the first electrode and the second electrode. The macroscale structure comprises a composite arrangement of nanocrystalline particles. The nanocrystalline particles comprise a lead chalcogenide material. The nanocrystalline particles establish conductive paths between the first electrode and the second electrode without an intervening conductive polymer agent.
H01L 31/0384 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including other non-monocrystalline materials, e.g. semiconductor particles embedded in an insulating material
G01T 1/24 - Measuring radiation intensity with semiconductor detectors
H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
H01L 31/08 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
74.
COMPOSTIONS AND METHODS FOR TREATING PROSTATE CANCER
The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for characterizing and treating prostate cancer (e.g., castration-resistant prostate cancer).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A dynamic standing desk having a work surface configured to move with planar motion parallel with the ground and with a range of movement that adjusts as a function of the size of a user of the desk. The desk may include a base, a tabletop that includes the work surface, a frame that movably couples the tabletop to the base, and at least one actuator configured to provide the planar motion. The desk may be used to reduce lower musculoskeletal discomfort of a user of the desk by oscillating the work surface of the desk with a range of movement based on a length of a limb of the user.
A47B 21/03 - Tables or desks specially adapted for use at individual computer workstations, e.g. for word processing or other manual data entry; Tables or desks specially adapted for typing; Auxiliary devices for attachment to such tables or desks characterised by adjustable parts, e.g. universally adjustable leaves, arm rests, wrist supports or mouse platforms the parts being horizontally adjustable, e.g. extensible, only
A47B 21/02 - Tables or desks specially adapted for use at individual computer workstations, e.g. for word processing or other manual data entry; Tables or desks specially adapted for typing; Auxiliary devices for attachment to such tables or desks characterised by adjustable parts, e.g. universally adjustable leaves, arm rests, wrist supports or mouse platforms the parts being vertically-adjustable only
Pervasive and interactive displays promise to present digital content seamlessly throughout a room. However, traditional display technologies do not scale to room-wide applications due to high per-unit-area costs and the need for constant wired power and data infrastructure. This disclosure proposes the use of photochromic paint as a display medium. Applying the paint to any surface or object creates ultra-low-cost displays, which can change color when exposed to specific wavelengths of light. New paint formulations are developed that enable wide area application of photochromic material. Along with a specially modified wide-area laser projector and depth camera that can draw custom images and create on-demand, room-wide user interfaces on photochromic enabled surfaces. System parameters such as light intensity, material activation time, and user readability are examined to optimize the display. Results show that images and user interfaces can last up to 16 minutes and can be updated indefinitely.
The disclosure is directed to binding agents, e.g., a single chain variable fragment (scFv) that specifically binds to a flavivirus NS1 protein, as well as compositions comprising the binding agent and a method of using such compositions to induce an immune response against a flavivirus (e.g., a dengue virus). The disclosure also provides a conjugate comprising the binding agent, and a recombinant NS1 antigen.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
79.
COMPACT HYBRID METAL CORE AND INDUCTOR PCB RECTIFIER FOR EV WIRELESS CHARGING
Toyota Motor Engineering & Manufacturing North America, Inc. (USA)
The Regents of the University of Michigan (USA)
Toyota Jidosha Kabushiki Kaisha (Japan)
Inventor
Liu, Yanghe
Liu, Guanliang
Wang, Mengqi
Zhou, Feng
Ukegawa, Hiroshi
Abstract
A rectifier apparatus for a wireless inductive charging system includes a first PCB having a metal layer, a dielectric layer provided on a surface of the metal layer, and a circuit layer provided on an opposite surface of the dielectric layer relative to the metal layer, the circuit layer including copper traces and circuit components, the circuit components including a capacitor array. The apparatus includes a second PCB having a non-metallic substrate and a plurality of inductors formed in the non-metallic substrate, each inductor comprised of a magnetic core and metallic windings, where the plurality of inductors are electrically coupled forming an inductor array. The circuit layer of the first PCB and the inductor array of the second PCB are electrically coupled to form a rectifier circuit to provide DC power. The circuit layer and the inductor array can be electrically coupled via aligned contact pads on each PCB.
The following relates generally to an injectable cardiac monitor. In some embodiments, an injectable cardiac monitor includes: a sensor configured to detect a cardiac signal from a mammal; a processor configured to process the detected cardiac signal; a transmitter configured to transmit the processed signal to a computing device; and a capsule for injecting into the mammal. In some implementations, the capsule includes: a body configured to enclose all of the sensor, the processor, and the transmitter; and wings configured to, upon deployment into the mammal, deploy outwardly from the body of the capsule.
A method of treating a T-cell mediated disease in a subject by administering to the subject a therapeutically effective amount of an antibody or fragment thereof that specifically binds to CD6 is described. Humanized antibodies useful for the method are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An integrated vascular delivery system having a frame configured to receive a catheter insertable in a patient to deliver fluid at an insertion site. The frame includes a first hub, a second hub, and a pair of flexible lateral members extending between the hubs and including a tubular lateral member. The system also includes a fluidic channel that fluidically communicates with the catheter, wherein the fluidic channel passes through the tubular lateral member and at least one of the hubs, and includes a fixed turnabout portion in which fluid flows in a direction different from that within the catheter. The first and second hubs provide anchoring points on the patient distributed around the insertion site and on opposite ends of the catheter, thereby anchoring the frame to the patient and stabilizing the catheter. A method is provided for using an integrated vascular delivery system.
A microscale collector and injector device comprises a microscale passive pre-concentrator (μPP) and a microscale progressively-heated injector (μPHI). The μPP devices comprises first and second substrate portions, a first collection material, a μPP heater, and an outlet. The first substrate portion defines an array of microscale diffusion channels. The first and second substrate portions cooperate to define a first compartment in fluid communication with the diffusion channels. The first collection material is disposed within the first compartment, at least partially surrounding the outlet. The μPP heater is disposed in thermal communication with the second substrate portion. The μPHI device comprises third and fourth substrate portions, a second collection material, and a plurality of μPHI heaters. The third and fourth substrate portions cooperate to define a second compartment. The second collection material is disposed within the second compartment. The μPHI heaters are disposed in thermal communication with the second compartment.
The present disclosure relates to an apparatus for conducting gynecological or proctological exams. The apparatus including a sensor body having a longitudinal axis, a proximal end, a distal end, a first passage disposed coaxial with the longitudinal axis and passing through the sensor body from the proximal end to the distal end, and a second passage including a first opening disposed proximate the distal end of the sensor body. Additionally, the apparatus includes a grip disposed on the proximal end of the sensor body, the grip including a second opening of the second passage. Further, the present disclosure provides a brush control mechanism having a proximal end and a distal end, the proximal end of the brush control mechanism configured to pass through the first passage from the distal end of the sensor body; and a brush disposed on the distal end of the brush control mechanism.
A61B 1/303 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the vagina, i.e. vaginoscopes
A61B 1/31 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the rectum, e.g. proctoscopes, sigmoidoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A method is presented for tracking an ingestible device in a gastrointestinal tract of a subject. The method includes: measuring acceleration of the ingestible device as it traverses through the gastrointestinal tract, for example using an accelerometer disposed in the ingestible device; computing a metric from the acceleration measurements obtained by the accelerometer over a given period of time; and identifying a location in the gastrointestinal tract based in part on the metric.
The present disclosure provides compositions and methods employing stem cell-derived amnion tissue. In some embodiments, compositions (e.g., scaffolds and devices) and methods of generating amnion-like tissues from hPSCs are provided. In some embodiments, uses of such cells for research, compound screening and analysis, and therapeutics are provided.
A system for sharing sensor data between a vehicle and a plurality of remote system generally includes a vehicle communication system, a three-dimensional (3D) sensor, and a controller. The controller is programmed to generate an initial 3D point cloud using the 3D sensor, generate an occupancy grid map based on the initial 3D point cloud, and select a producer remote system to provide data for a cell of the occupancy grid map classified as a first blindspot. The controller is further programmed to send a data request to the producer remote system using the vehicle communication system, receive data from the producer remote system including information about the cell of the occupancy grid map classified as the first blindspot, generate a merged 3D point cloud by merging the data received from the producer remote system with the initial 3D point cloud, and identify objects using the merged 3D point cloud.
H04W 4/44 - Services specially adapted for particular environments, situations or purposes for vehicles, e.g. vehicle-to-pedestrians [V2P] for communication between vehicles and infrastructures, e.g. vehicle-to-cloud [V2C] or vehicle-to-home [V2H]
G08G 1/0969 - Systems involving transmission of navigation instructions to the vehicle having a display in the form of a map
A device includes a substrate having a surface, an array of conductive projections supported by the substrate and extending outward from the surface of the substrate, a plurality of catalyst nanoparticles disposed over the array of conductive projections, and an oxide layer covering the plurality of catalyst nanoparticles and the array of conductive projections. The oxide layer has a thickness on the order of a size of each catalyst nanoparticle of the plurality of catalyst nanoparticles.
C25B 11/067 - Inorganic compound e.g. ITO, silica or titania
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
C25B 11/02 - Electrodes; Manufacture thereof not otherwise provided for characterised by shape or form
C25B 11/053 - Electrodes comprising one or more electrocatalytic coatings on a substrate characterised by multilayer electrocatalytic coatings
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
C23C 28/00 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and
89.
Injector device for arrhythmia classification using measurement of cardiac activity and power analysis
The following relates generally to an injector for injecting a cardiac monitor. In some embodiments, an injector includes: a push-rod configured to be inserted into a case at a first end of the case, where the case is configured to hold the injectable cardiac monitor. In some embodiments, the case includes: a first handle protruding from a first side of the case; a second handle protruding from a second side of the case; and a beveled needle configured to be attached to a second end of the case, and configured to be inserted into a mammal to inject the injectable cardiac monitor into the mammal.
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A computer-implemented method is presented for modeling the genome of a cell. The method includes: constructing a graph for a genome, where each node in the graph represents a gene in the genome and each edge in the graph quantifies the relationship between two genes; receiving a first biological sample of a first cell of a subject, where the first cell has a first cell type; determining gene expression data for the first cell from the first biological sample; extracting a first subgraph from the graph using the gene expression data for the first cell, where the subgraph represents the first cell type; receiving a second biological sample of a second cell of a subject, where the second cell has a second cell type; determining gene expression data for the second cell from the second biological sample; extracting a second subgraph from the graph using the gene expression data for the second cell, where the second subgraph represents a second cell type; and comparing the first subgraph to the second subgraph.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
A power converter device includes power converter circuitry that includes multiple inductors. The power converter circuitry may convert an input voltage and current to an output voltage and current at a variable frequency via operation of the multiple inductors. The power converter device further includes control circuitry configured to implement cycle-by-cycle current output analysis to synchronize the multiple inductors to a particular current output characteristic of a first one of the multiple inductors.
H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
H02M 3/157 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators with digital control
A method of material casting includes knitting, by a computer-controlled knitting machine, a flexible formwork, where the flexible formwork defines a partially-closed shape having a plurality of topological features, filling the flexible formwork with a casting material, and deforming the flexible formwork with the casting material. In some cases, the method includes removing the casting material from the flexible formwork when the flexible formwork has imparted the shape on the casting material.
D04B 15/66 - Devices for determining or controlling patterns
D04B 1/22 - Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes specially adapted for knitting goods of particular configuration
A computer-implemented method is presented for scanning a computer network. The method includes: a) sending a particular network probe to a network address in a computer network; b) receiving a response to the network probe from the network address; c) appending the response to a set of features forming a feature vector; d) determining a next network probe to conduct at the network address; and e) predicting, by the computer processor, the response from the next network probe using the feature vector and a model, where the model is trained using a machine learning method and outputs a probability that a given network address will respond to a network probe.
H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence
Provided herein is technology relating to calorimetry and particularly, but not exclusively, to apparatuses, methods, and systems for making high-resolution thermodynamic measurements of reactions between gas phase reactants and nanomaterials. For example, the technology can provide thermodynamic measurements with a high heat flow resolution and long term stability at a wide range of temperatures and reaction pressures. The technology is used, for example, to study the thermodynamics of surface reactions and phase transformations in nanomaterials.
G01N 25/48 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
95.
DONOR-ACCEPTOR-DONOR TYPE MATERIALS FOR OPTOELECTRONIC APPLICATIONS
Provided are compounds of Formula I. Also provided are formulations comprising these compounds. Further provided are optoelectronic devices that utilize these compounds.
Provided are compounds of Formula I. Also provided are formulations comprising these compounds. Further provided are optoelectronic devices that utilize these compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A method for denoising magnetic resonance images and data is disclosed herein. An example method includes receiving a series of MRF images from a scanning device; identifying one or more subsets of voxels for the series of MRF images; generating one or more sets of eigenvectors, each set of the one or more sets of eigenvectors corresponding to one of the one or more subsets of voxels, and each eigenvector of the one or more sets of eigenvectors having a corresponding eigenvalue; applying a noise distribution model to each of the eigenvalues; identifying a subset of the eigenvalues as corresponding to noise based on the noise distribution model; and reconstructing the series of MRF images without the subset of eigenvalues identified as corresponding to noise.
A nanowire can include a first semiconductor portion, a second portion including a quantum structure disposed on the first portion, and a second semiconductor portion disposed on the second portion opposite the first portion. The quantum structure can include one or more quantum core structures and a quantum core shell disposed about the one or more quantum core structures. The one or more quantum core structures can include one or more quantum disks, quantum arch-shaped forms, quantum wells, quantum dots within quantum wells or combinations thereof.
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
G02B 6/122 - Basic optical elements, e.g. light-guiding paths
H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
98.
PHOTOCATALYST SUSPENSION REACTOR FOR SOLAR FUEL FORMATION
A photocatalyst suspension reactor for solar fuel formation. The reactor may comprise a shallow pool filled with a first portion of an electrolyte solution. The electrolyte solution may comprise a solvent, a plurality of redox shuttle molecules, and a plurality of photocatalyst particles. The reactor may further comprise a plurality of tubes disposed on a surface of the shallow pool, each tube of the plurality of tubes comprising an upper half and a lower half. The upper half may comprise a transparent material configured to be minimally permeable to hydrogen gas and oxygen gas. The lower half may be configured to be filled with a second portion of the electrolyte solution and comprises an ion bridge material permeable to the plurality of redox shuttle molecules and minimally permeable to the plurality of photocatalyst particles.
B01J 8/08 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with moving particles
B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
C01B 3/50 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification
99.
COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS
The present invention relates to nanoparticles complexed with N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide (ML355) configured for treating cardiovascular related disorders. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying ML355 configured for treating cardiovascular related disorders (e.g., inhibit platelet aggregation; inhibit thrombosis formation; inhibit vessel occlusion; inhibit platelet associated 12-LOX activity, as well as systems and methods utilizing such sHDL nanoparticles (e.g., therapeutic settings).
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
An apparatus (e.g., for cell culture for in vitro growth of tissues and/or organs) includes a base, a plate on the base, and a removable barrier component on the plate. The removable barrier component is configured to at least partially define a first region. The removable barrier component includes a bottom surface and a top surface. The bottom surface configured to be in contact with the plate. The top surface is opposite the bottom surface. The press is configured to engage the top surface of the removable barrier component to apply a predetermined pressure to the removable barrier component. The removable barrier component is between the press and the plate. A joint between the plate and the removable barrier component may be substantially impermeable to live cells. The apparatus may further include a removable cover that engages the base to enclose the plate, the removable barrier component, and the press.
patents
